Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Revelation Biosciences advances its Gemini acute kidney injury program toward the Phase 2/3 TITAN study after selecting Avance Clinical to support pivotal trial execution and hospital-based patient recruitment. Representative image.
Pharma & Biotech

Revelation Biosciences has its CRO for TITAN. Now Gemini faces the acute kidney injury test that really matters

Revelation Biosciences names Avance Clinical for the Phase 2/3 TITAN study as Gemini approaches its pivotal acute kidney injury test.

Read More
FairJourney Bio’s antibody engineering work is advancing a tumor-conditional IL-12 approach designed to activate potent cytokine signaling more selectively within the tumor microenvironment, potentially addressing one of IL-12 therapy’s longstanding toxicity challenges. Representative image.
Pharma & Biotech

Can FairJourney Bio’s reversible antibody switch solve IL-12’s decades-old toxicity problem?

FairJourney Bio engineers a tumor-conditional IL-12 switch designed to limit systemic exposure and localize cytokine activation in solid tumors.

Read More
Tolerance Bio’s license for NeoImmuneTech’s clinical-stage long-acting interleukin-7 therapy efineptakin alfa strengthens its push into thymic function and immune-resilience research, bringing an established human-stage asset into its emerging thymus-focused pipeline. Representative image.
Pharma & Biotech

Tolerance Bio has found a faster route into the clinic, but can efineptakin alfa protect thymic function?

Tolerance Bio licenses efineptakin alfa from NeoImmuneTech, adding clinical-stage IL-7 to its thymus and immune-resilience strategy.

Read More
Network Bio is working with NVIDIA Corporation to scale a population-level cell-free RNA foundation model aimed at disease detection, biomarker discovery and drug development, highlighting how medical AI could increasingly combine blood-derived molecular signals with large clinical datasets. Representative image.
Medical Devices & Diagnostics

How Network Bio and NVIDIA plan to turn cell-free RNA into disease-spanning medical intelligence

Network Bio and NVIDIA are scaling a cfRNA foundation model for disease detection, biomarker discovery and drug development across biobanks.

Read More
NTx Bio’s RNA manufacturing technology supports Baylor College of Medicine’s production workflow for Diakonos Oncology’s DOC1021 personalized cancer vaccine in a Phase 1/2 refractory melanoma trial, highlighting the manufacturing challenge behind patient-specific cancer immunotherapies. Representative image.
Pharma & Biotech

NTx Bio supports Baylor manufacturing for Diakonos Oncology’s DOC1021 Phase 1/2 melanoma trial

NTx Bio enters the DOC1021 manufacturing workflow as Diakonos tests a personalized dendritic cell therapy in refractory melanoma.

Read More
Aztron Medtech’s TendMIN Achilles tendon repair system has now surpassed 200 U.S. procedures as the company accelerates commercial expansion following its Taiwan Presidential Award win. Representative image.
Medical Devices & Diagnostics

Aztron Medtech just doubled TendMIN’s U.S. procedure count. Can the next financing round turn early adoption into scale?

Aztron Medtech wins a Taiwan Presidential Award as TendMIN passes 200 U.S. procedures and the company prepares its next financing round.

Read More
Zipalertinib Phase 3 REZILIENT3 data are set for WCLC 2026 as attention turns to whether the first-line combination can strengthen treatment options for EGFR exon 20 insertion-positive non-small cell lung cancer. Representative image.
Pharma & Biotech

Taiho Oncology and Cullinan Therapeutics prepare pivotal zipalertinib data for WCLC 2026

Zipalertinib’s pivotal REZILIENT3 data will debut at WCLC 2026 after the first-line lung cancer trial met its PFS endpoint.

Read More
IntraBio’s pivotal Phase III CACNA1A trial is enrolling patients as levacetylleucine moves into a key clinical test, with recruitment expected to be completed in October 2026. Representative image.
Pharma & Biotech

What IntraBio’s IB1001-304 Phase III trial could reveal about CACNA1A treatment

IntraBio’s Phase III CACNA1A trial is enrolling, with October recruitment completion targeted as levacetylleucine enters a pivotal test.

Read More
Cardio Diagnostics begins in-house processing of Epi+Gen CHD and PrecisionCHD tests at its new high-complexity CLIA-certified laboratory in Iowa City, bringing cardiovascular diagnostic testing, quality control and turnaround management under one roof. Representative image.
Medical Devices & Diagnostics

Cardio Diagnostics now controls its own cardiac test lab, but can CLIA certification unlock meaningful scale?

Cardio Diagnostics starts in-house Epi+Gen CHD and PrecisionCHD processing in Iowa. See what CLIA certification means for margins and adoption.

Read More
GenBio AI’s human cell world model aims to bring genomics, proteins, cellular morphology and AI-driven simulation into a single virtual biology framework, potentially helping researchers test drug and genetic interventions before moving promising hypotheses into the wet lab. Representative image.
Pharma & Biotech

Can AI simulate a human cell before the wet lab? GenBio AI says its world model brings the idea closer

GenBio AI has unveiled a virtual cell world model spanning biological scales. See what it can simulate and what still needs validation.

Read More